Related Experiment Video
Updated: May 14, 2026

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
Harmonizing Perspectives on MPS II Care in Türkiye: A Delphi Study Towards Treatment Management Consensus
Neslihan Onenli Mungan1, Leyla Tumer2, Serap Sivri3
1Department of Pediatrics, Division of Pediatric Metabolism, Cukurova University Faculty of Medicine, Adana 01790, Türkiye.
Abstract:
Background: Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by pathogenic variants in the iduronate-2-sulfatase gene, leading to progressive multisystem involvement. Although international management guidelines exist, challenges in their implementation across different healthcare systems remain insufficiently addressed. This study aimed to establish a national expert consensus in Türkiye on the treatment and management of MPS II, aligning local practice with international standards. Methods: A modified Delphi methodology was conducted using two rounds of online surveys supported by three steering committee meetings. The process involved 10 experienced clinicians and a scientific committee of six professors. Based on international guidelines and country-specific clinical challenges, 72 consensus statements and 84 exploratory questions were developed. Statements achieving ≥ 80% agreement were accepted as consensus. Results: Consensus supported initiating enzyme replacement therapy (ERT) in both severe and attenuated MPS II, guided by functional and cognitive status. Severe cognitive impairment was not considered an exclusion criterion for ERT, given its somatic benefits. Experts agreed on continuing ERT into adulthood with individualized discontinuation decisions. Routine evaluations every 6-12 months, including respiratory, cardiac, and neurocognitive assessments, were recommended. Additional consensus areas included individualized premedication strategies, structured transition to adult care, selective home infusion, annual patient-reported outcome assessments, and the establishment of a national MPS II registry. Hematopoietic stem cell transplantation was not endorsed. Conclusions: This Delphi study demonstrates strong expert consensus on MPS II management in Türkiye, providing a practical framework to guide clinical practice, support alignment with international recommendations, and inform future policy and research priorities.
Insights
This study established a national expert consensus in Türkiye for managing Mucopolysaccharidosis type II (MPS II; Hunter syndrome). Key recommendations include enzyme replacement therapy (ERT) for all patients and regular monitoring, aligning local practice with global standards.
Area of Science:
- Rare genetic disorders
- Lysosomal storage diseases
- Clinical practice guidelines
Background:
- Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare X-linked lysosomal storage disorder.
- Pathogenic variants in the iduronate-2-sulfatase gene cause progressive multisystem involvement.
- International guidelines exist, but implementation challenges persist.
Purpose of the Study:
- To establish a national expert consensus in Türkiye for MPS II treatment and management.
- To align local clinical practice with international standards for MPS II care.
- To address country-specific challenges in managing MPS II.
Main Methods:
- Modified Delphi methodology with two rounds of online surveys.
- Involved 10 experienced clinicians and a six-professor scientific committee.
- Developed 72 consensus statements and 84 exploratory questions based on guidelines and local challenges.
Main Results:
- Consensus supported enzyme replacement therapy (ERT) for all MPS II types, irrespective of cognitive impairment, due to somatic benefits.
- Recommended routine evaluations (respiratory, cardiac, neurocognitive) every 6-12 months and individualized ERT continuation into adulthood.
- Agreed on individualized premedication, transition to adult care, home infusion, patient-reported outcomes, and a national registry; hematopoietic stem cell transplantation was not endorsed.
Conclusions:
- The Delphi study achieved strong expert consensus on MPS II management in Türkiye.
- Provides a practical framework to guide clinical practice and align with international recommendations.
- Informs future policy and research priorities for MPS II in Türkiye.
Related Concept Videos
Interdisciplinary Care: The Health Care Team-II
Physical Therapist
A physical therapist (PT) aims to restore function or prevent additional impairment in a patient following an injury or disease. Massage, heat, cold, water, sonar waves, exercises, and electrical stimulation are some treatments used by PTs to treat...
Therapeutic Drug Monitoring: Affecting Factors
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Therapeutic Drug Monitoring: Overview and Classification
Drug Therapy
Antianxiety Medications